AstraZeneca PLC (LON: AZN)

Market Cap	171.37B
Revenue (ttm)	38.20B
Net Income (ttm)	4.85B
Shares Out	1.55B
EPS (ttm)	3.10
PE Ratio	35.69
Forward PE	15.09
Dividend	2.34 (2.16%)
Ex-Dividend Date	Aug 8, 2024

Volume	1,319,774
Average Volume	2,204,171
Open	10,832
Previous Close	10,794
Day's Range	10,790 - 11,052
52-Week Range	9,461 - 13,388
Beta	0.19
RSI	54.35
Earnings Date	Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 89,900
• Stock Exchange: London Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.

Financial numbers in USD